Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ASO Visual Abstract: High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival Following Resection of Extremity and Truncal Soft-Tissue Sarcoma.
Traweek RS, Lyu H, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. Traweek RS, et al. Among authors: nassif ef. Ann Surg Oncol. 2024 Mar 28. doi: 10.1245/s10434-024-15201-3. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38546800 No abstract available.
High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival (RFS) After Resection of Extremity and Truncal Soft Tissue Sarcoma.
Traweek RS, Lyu HG, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. Traweek RS, et al. Among authors: nassif ef. Ann Surg Oncol. 2024 Feb 23. doi: 10.1245/s10434-024-15074-6. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38396039
Targeting the Molecular and Immunologic Features of Leiomyosarcoma.
Cope BM, Traweek RS, Lazcano R, Keung EZ, Lazar AJ, Roland CL, Nassif EF. Cope BM, et al. Among authors: nassif ef. Cancers (Basel). 2023 Mar 31;15(7):2099. doi: 10.3390/cancers15072099. Cancers (Basel). 2023. PMID: 37046760 Free PMC article. Review.
Myxoid Liposarcomas: Systemic Treatment Options.
Nassif EF, Keung EZ, Thirasastr P, Somaiah N. Nassif EF, et al. Curr Treat Options Oncol. 2023 Apr;24(4):274-291. doi: 10.1007/s11864-023-01057-4. Epub 2023 Feb 28. Curr Treat Options Oncol. 2023. PMID: 36853469 Review.
The Landscape of Immunotherapy for Retroperitoneal Sarcoma.
Gingrich AA, Nassif EF, Roland CL, Keung EZ. Gingrich AA, et al. Among authors: nassif ef. Curr Oncol. 2023 Feb 9;30(2):2144-2158. doi: 10.3390/curroncol30020165. Curr Oncol. 2023. PMID: 36826126 Free PMC article. Review.
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.
Traweek RS, Cope BM, Roland CL, Keung EZ, Nassif EF, Erstad DJ. Traweek RS, et al. Among authors: nassif ef. Front Oncol. 2022 Nov 10;12:1006959. doi: 10.3389/fonc.2022.1006959. eCollection 2022. Front Oncol. 2022. PMID: 36439412 Free PMC article. Review.
The immune landscape of undifferentiated pleomorphic sarcoma.
Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. Lazcano R, et al. Among authors: nassif ef. Front Oncol. 2022 Oct 12;12:1008484. doi: 10.3389/fonc.2022.1008484. eCollection 2022. Front Oncol. 2022. PMID: 36313661 Free PMC article.
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Thirasastr P, et al. Among authors: nassif ef. Cancer Med. 2023 Feb;12(4):4282-4293. doi: 10.1002/cam4.5298. Epub 2022 Sep 24. Cancer Med. 2023. PMID: 36151848 Free PMC article.
69 results